Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Adjuvant Therapy in High-Grade Soft Tissue Sarcoma
NCT03951571Phase 2Completed
- Sponsor
- Fudan University
- Start
- May 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in soft tissue sarcoma (STS) comparing Anlotinib Group with Placebo Group (2 arms). Primary endpoints: Disease-Free Survival at 2 years and Disease-Free Rate at 2 years. Started May 2019; status: completed.
02
Drugs
anlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03951571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951571.